<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.101011</article-id><article-id pub-id-type="publisher-id">TCM-39927</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210100000_92787995.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  补心软脉颗粒对气阴两虚夹有瘀热型心绞痛的临床疗效观察
  Clinical Effect of “BuXinRuanMai”Granule on Angina Pectoris of Qi-Yin Deficiency and Blood Stasis-Heat Type
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>严</surname><given-names>冬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>宁</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>甜</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南京中医药大学附属医院，江苏 南京 </addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>南京中医药大学附属医院，江苏 南京</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>01</month><year>2021</year></pub-date><volume>10</volume><issue>01</issue><fpage>89</fpage><lpage>96</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：观察补心软脉颗粒治疗气阴两虚夹有瘀热型心绞痛的临床疗效。方法：将符合诊断的心绞痛患者随机分为对照组20例，治疗组20例，对照组予常规西药治疗，治疗组在常规西药治疗的基础上加用补心软脉颗粒，连续服用8周，4周为1疗程，观察两个疗程。观察两组在治疗前后各项指标的变化。结果：1) 补心软脉组明显缓解心绞痛症状、改善中医证候，与对照组相比，P &lt; 0.05；2) 明显减低血清中TC、TG、LDL，提高HDL水平，显著优于对照组，P &lt; 0.05；3) 降低全血粘度水平、血浆粘度、红细胞刚性指数、D2聚体、FIB含量，疗效优于对照组，P &lt; 0.05；4) 治疗后两组血清中hs-CRP水平均有所下降，但组间无统计学差异。结论：补心软脉颗粒在治疗气阴两虚夹有瘀热证冠心病患者中有较好的临床疗效，并能调节脂质代谢、改善血液流变。 Objective: To observe the clinical efficacy of “BuXinRuanMai” (BXRM) granule in angina pectoris with “Qi-Yin deficiency” and “Stagnant Heat”. Methods: Patients with angina pectoris were ran-domly divided into the control group and the treatment group. Each group had 20 patients. Pa-tients in the control group received conventional western medicine, and patients in the treatment group received “BXRM” granule additionally. Each group needed to take medicine for eight weeks to observe the curative effect. Result: 1) “BXRM” granule could not only relieve the symptoms of angina in patients, but also improve the syndromes. Compared with the control group, “BXRM” granule had significant curative effect (P &lt; 0.05); 2) The treatment group could significantly reduce more in the serum TC, TG, LDL, raised high in the HDL levels, than the control group (P &lt; 0.05); 3) The treatment group reduced more in the whole blood viscosity, plasma viscosity, erythrocyte rigidity index, D-D-dimer, and fibrinogen (FIB) content, than the control group (P &lt; 0.05); 4) In the aspect of the inflammatory responses, CRP levels in two groups of patients after treatment were decreased, but there was no significant difference. Conclusion: “BXRM” granule had better clinical efficacy in the coronary heart disease patients with “Qi-Yin deficiency” and “Stagnant Heat”. At the same time, it regulated lipid metabolism and improved blood hemorheology. 
  
 
</p></abstract><kwd-group><kwd>补心软脉颗粒，气阴两虚夹有瘀热，心绞痛，临床研究, “BuXinRuanMai” Granule</kwd><kwd> Deficiency of Both Qi and Yin and Blood Stasis and Extreme Heat</kwd><kwd> Angina Pectoris</kwd><kwd> Clinical Research</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察补心软脉颗粒治疗气阴两虚夹有瘀热型心绞痛的临床疗效。方法：将符合诊断的心绞痛患者随机分为对照组20例，治疗组20例，对照组予常规西药治疗，治疗组在常规西药治疗的基础上加用补心软脉颗粒，连续服用8周，4周为1疗程，观察两个疗程。观察两组在治疗前后各项指标的变化。结果：1) 补心软脉组明显缓解心绞痛症状、改善中医证候，与对照组相比，P &lt; 0.05；2) 明显减低血清中TC、TG、LDL，提高HDL水平，显著优于对照组，P &lt; 0.05；3) 降低全血粘度水平、血浆粘度、红细胞刚性指数、D-D-二聚体、FIB含量，疗效优于对照组，P &lt; 0.05；4) 治疗后两组血清中hs-CRP水平均有所下降，但组间无统计学差异。结论：补心软脉颗粒在治疗气阴两虚夹有瘀热证冠心病患者中有较好的临床疗效，并能调节脂质代谢、改善血液流变。</p></sec><sec id="s2"><title>关键词</title><p>补心软脉颗粒，气阴两虚夹有瘀热，心绞痛，临床研究</p></sec><sec id="s3"><title>Clinical Effect of “BuXinRuanMai” Granule on Angina Pectoris of Qi-Yin Deficiency and Blood Stasis-Heat Type</title><p>Dong Yan, Ning Wang, Tian Yang</p><p>Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing Jiangsu</p><p><img src="//html.hanspub.org/file/11-2270634x4_hanspub.png" /></p><p>Received: Dec. 28<sup>th</sup>, 2020; accepted: Jan. 13<sup>th</sup>, 2021; published: Jan. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/11-2270634x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To observe the clinical efficacy of “BuXinRuanMai” (BXRM) granule in angina pectoris with “Qi-Yin deficiency” and “Stagnant Heat”. Methods: Patients with angina pectoris were randomly divided into the control group and the treatment group. Each group had 20 patients. Patients in the control group received conventional western medicine, and patients in the treatment group received “BXRM” granule additionally. Each group needed to take medicine for eight weeks to observe the curative effect. Result: 1) “BXRM” granule could not only relieve the symptoms of angina in patients, but also improve the syndromes. Compared with the control group, “BXRM” granule had significant curative effect (P &lt; 0.05); 2) The treatment group could significantly reduce more in the serum TC, TG, LDL, raised high in the HDL levels, than the control group (P &lt; 0.05); 3) The treatment group reduced more in the whole blood viscosity, plasma viscosity, erythrocyte rigidity index, D-D-dimer, and fibrinogen (FIB) content, than the control group (P &lt; 0.05); 4) In the aspect of the inflammatory responses, CRP levels in two groups of patients after treatment were decreased, but there was no significant difference. Conclusion: “BXRM” granule had better clinical efficacy in the coronary heart disease patients with “Qi-Yin deficiency” and “Stagnant Heat”. At the same time, it regulated lipid metabolism and improved blood hemorheology.</p><p>Keywords:“BuXinRuanMai” Granule, Deficiency of Both Qi and Yin and Blood Stasis and Extreme Heat, Angina Pectoris, Clinical Research</p><disp-formula id="hanspub.39927-formula3"><graphic xlink:href="//html.hanspub.org/file/11-2270634x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/11-2270634x7_hanspub.png" /> <img src="//html.hanspub.org/file/11-2270634x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>《金匮要略》中关于“胸痹心痛”的记载类似现代医学的冠心病心绞痛，并提出具体治疗方法，如栝楼薤白汤系列，一直沿用至今，得到临床的普遍认可。随着现代医学诊断手段的提高，以及病人数量的增加，传统的“阳微阴弦”的内涵得到进一步扩充。全国名老中医唐蜀华教授的50多年的临床经验发现“本虚标实”仍是冠心病心绞痛的病机根本，“本虚”是指气、血、阴、阳的亏虚；“标实”常为寒凝、气滞、血瘀、痰阻。其中又以气阴两虚夹有瘀血，为临床最常见病机，与文献报道 [<xref ref-type="bibr" rid="hanspub.39927-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39927-ref2">2</xref>] 的冠心病最常见证型气阴两虚夹有瘀血相吻合。并创立了具有独立知识产权的益气养阴、化瘀清热作用的补心软脉颗粒 [<xref ref-type="bibr" rid="hanspub.39927-ref3">3</xref>]，前期实验研究结果提示其具有明确的抗大鼠急性心肌缺血损伤作用、对麻醉犬急性心肌缺血的保护作用、其含药血清对Ang II诱导的HUVEC细胞具有抗氧化作用 [<xref ref-type="bibr" rid="hanspub.39927-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39927-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.39927-ref6">6</xref>]。本研究重在探讨补心软脉颗粒对气阴两虚夹有瘀热型冠心病心绞痛的临床疗效。</p></sec><sec id="s6"><title>2. 研究对象</title><sec id="s6_1"><title>2.1. 病例来源</title><p>病例来自2015年3月至2015年12月就诊于江苏省中医院心内科的门诊病人，将符合冠心病诊断的40例病人随机分为对照组20例，治疗组20例。经过江苏省中医院伦理委员会审查。</p></sec><sec id="s6_2"><title>2.2. 诊断标准</title><sec id="s6_2_1"><title>2.2.1. 西医诊断标准</title><p>参照2010年的《冠状动脉粥样硬化性心脏病诊断标准》和第14版《实用内科学》教科书制定。冠状动脉粥样硬化性心脏病简称冠心病，指因冠状动脉粥样硬化使管腔狭窄或阻塞导致的心肌缺血、缺氧而引起的心脏病。其特点是在劳累、情绪激动、受凉、饱餐等诱因下发作的，位于胸骨体上段或中段后，或放射至心前区、左上肢前内侧的压榨性、憋闷性或窒息性疼痛，持续数分钟至半小时不等，休息或含服硝酸甘油后可缓解，心电图示有缺血性改变或冠脉造影可确诊者。</p></sec><sec id="s6_2_2"><title>2.2.2. 中医诊断标准</title><p>目前尚缺乏气阴两虚夹有瘀热证统一的诊断标准，参照2002年第3版《中药新药临床研究指导原则》中关于胸痹的分型，根据气虚、阴虚、瘀热各自的特点，拟定诊断依据为：胸痛和/或胸闷，心悸、气短，神疲乏力，腰膝酸软，心烦少寐，头晕目眩，耳鸣，口干，舌胖红中有细裂少津，脉细数。</p></sec></sec><sec id="s6_3"><title>2.3. 纳入标准</title><p>符合西医冠心病心绞痛诊断标准及中医气阴两虚夹有瘀热证诊断标准的患者，年龄40~80岁，自愿参加，依从性良好者。</p></sec><sec id="s6_4"><title>2.4. 排除标准</title><p>1) 不符合西医及中医诊断标准的；2) 经检查证实近期(半年内)急性心肌梗死、主动脉夹层、心脏瓣膜病、心肌病及其他非心脏疾病所致胸痛者；3) 合并严重高血压、糖尿病、休克、心律失常，严重肝肾功能不全、造血系统障碍者及精神病患者；4) 妊娠期或哺乳期妇女；5) 过敏体质及对多种药物过敏者。</p></sec><sec id="s6_5"><title>2.5. 剔除和中止实验标准</title><p>1) 不符合诊断标准而误纳入者；2) 受试者用药依从性差，影响药物疗效判断者；3) 资料不全者；4) 治疗过程中发现严重并发症或病情加剧者；5) 治疗中有严重不良反应或对药物过敏者；6) 自行退出试验者。</p></sec></sec><sec id="s7"><title>3. 研究方法</title><sec id="s7_1"><title>3.1. 治疗方法</title><p>将符合诊断的气阴两虚夹有瘀热证的冠心病心绞痛患者随机分为两组：对照组20例，治疗组(补心软脉组) 20例，对照组予以西药常规治疗，治疗组常规西药基础上加用补心软脉颗粒，服用8周，4周为1疗程，观察两个疗程。对照组：常规药物如抗血小板聚集、调脂、扩冠、控制血压及心率等治疗；治疗组：在抗血小板聚集、调脂、扩冠、控制血压及心率等药物治疗的基础上，加服补心软脉颗粒剂(江阴天江制药厂生产，其中银杏叶由扬子江制药厂生产，39.2 mg∙tid)，温水冲服，每天1剂，分早晚服用。</p></sec><sec id="s7_2"><title>3.2. 观察指标</title><p>1) 相关症状及体征：心绞痛发作的频率、程度及持续时间，血压、心率的变化；2) 中医症状的改变；3) 心电图变化；4) 血清学指标：① 血脂：TC、TG、LDL-C、HDL-C；② 血液流变学：全血高切、低切粘度、血浆粘度、红细胞刚性指数；③ 其他：纤维蛋白原、D-D二聚体、C-反应蛋白等；5) 安全性指标：血、尿、粪常规，肝(AST、ALT)，肾功能(Cr、BUN)。</p></sec><sec id="s7_3"><title>3.3. 疗效评定标准</title><p>参照《中药新药临床研究指导原则》及《冠心病心绞痛及心电图疗效判定标准》。</p><sec id="s7_3_1"><title>3.3.1. 西医证候疗效评定标准</title><p>1) 心绞痛临床疗效评定标准：显效：主要症状消失或达到显效标准；有效：主要症状减轻或达到有效标准；无效：症状无明显改善；加重：症状较治疗前加重。</p><p>2) 心电图疗效评定标准：显效：心电图恢复至大致正常或达到正常心电图；</p><p>有效：ST段的降低，以治疗后回升0.05 mV以上，但未达正常水平，在主要导联倒置T波改变变浅(达25%以上者)；或T波由平坦变为直立，房室或室内传导阻滞改善者；无效：心电图基本与治疗前相同；加重：ST段较治疗前降低0.05 mV以上，在主要导联倒置T波加深(达25%以上)，或直立T波变平坦，平坦T波变倒置，以及出现异位心律I房室或室内传导阻滞。</p><p>3) 反应血栓、炎症的疗效评定：根据D-D-二聚体、纤维蛋白原、hs-CRP的测定值进行评定；</p></sec><sec id="s7_3_2"><title>3.3.2. 中医证候疗效评定标准</title><p>根据患者胸痛、胸闷、心悸、气短、神疲乏力、不寐、舌质、舌苔、脉象情况评判患者中医证候积分，根据积分法判定中医证候疗效，疗效指数(n) = (疗前积分 − 疗后积分)/疗前积分。显效：临床症状、体征明显改善，n ≥ 70%；有效：临床症状、体征均有好转，n ≥ 30%；无效：临床症状、体征无明显改善，甚或加重，n &lt; 30%；加重：临床症状、体征均有加重，n &lt; 0。</p></sec></sec><sec id="s7_4"><title>3.4. 数据处理</title><p>选用SPSS 22.0软件进行统计，计数资料采用卡方检验，计量资料用均数 &#177; 标准差( X &#175; &#177; S)进行统计描述分析，两组间或治疗前后采用t检验，P &lt; 0.05有统计学意义，提示有显著差异。</p></sec></sec><sec id="s8"><title>4. 研究结果</title><sec id="s8_1"><title>4.1. 两组患者性别、年龄比较</title><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The distribution of sex and age in two groups ( X &#175; &#177; S</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >男</th><th align="center" valign="middle" >女</th><th align="center" valign="middle" >平均年龄</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >66.75 &#177; 8.097</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >64.30 &#177; 9.685</td></tr></tbody></table></table-wrap><p>表1. 两组患者性别、年龄分布( X &#175; &#177; S)</p><p>注：治疗前两组年龄、性别比较：P &gt; 0.05。</p><p>表1显示：对照组男性占50%，女性占50%，治疗组男性占40%，女性占60%，两组冠心病患者的性别经X<sup>2</sup>检验，P = 0.525 (P &gt; 0.05)，无统计学差异；两组患者组间平均年龄经t检验，P = 0.705 (P &gt; 0.05)，无统计学差异，说明对照组和治疗组的性别、平均年龄均具有可比性。</p></sec><sec id="s8_2"><title>4.2. 两组患者心绞痛临床疗效比较</title><p>表2显示：对照组的总有效率达60.0%，补心软脉组的总有效率达95.0%，两组患者心绞痛临床疗效经X<sup>2</sup>检验，P = 0.030，有统计学差异，说明补心软脉组改善心绞痛的临床疗效优于对照组。</p></sec><sec id="s8_3"><title>4.3. 治疗后两组患者心电图临床疗效比较</title><p>表3显示，治疗组有效率达95.0%，对照组总有效率达70.0%，两组间总有效率采用检验进行统计分析，X<sup>2</sup> = 4.328，P &lt; 0.05，有统计学差异，说明在西药的基础上加用补心软脉颗粒可以有效改善心电图变化，而且优于单纯西药治疗。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of curative effect of Angina Pectoris between two groups after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >显效</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >总有效率</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >60.0%</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >95.0%</td></tr></tbody></table></table-wrap><p>表2. 治疗后两组患者心绞痛疗效比较</p><p>注：治疗后两组心绞痛疗效对比，X<sup>2</sup>检验，P = 0.030。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of electrocardiographic efficacy between the two groups after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >显效</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >总有效率</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >70.0%</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >95.0%</td></tr></tbody></table></table-wrap><p>表3. 治疗后两组患者心电图疗效比较</p><p>注：治疗后两组疗效对比，X<sup>2</sup>检验，P = 0.037。</p></sec><sec id="s8_4"><title>4.4. 治疗前后两组患者中医证候积分比较</title><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of TCM Syndrome integral of two groups before and after treatment ( X &#175; &#177; S</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前积分</th><th align="center" valign="middle" >治疗后积分</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >23.70 &#177; 5.131</td><td align="center" valign="middle" >17.75 &#177; 4.876**</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >23.35 &#177; 4.545*</td><td align="center" valign="middle" >11.05 &#177; 2.064**<sup>△</sup></td></tr></tbody></table></table-wrap><p>表4. 治疗前后两组患者中医证候积分比较( X &#175; &#177; S)</p><p>注：治疗前两组间积分对比，*P = 0.669；治疗后与治疗前对比，**P = 0.028；治疗后两组间对比，△P = 0.002。</p><p>表4显示：治疗前，P &gt; 0.05，两组患者的证候积分无统计学差异，有可比性。治疗后与治疗前相比，P &lt; 0.05，说明两组治疗方法都能改善中医临床证候。治疗后两组间对比，P &lt; 0.05，显示补心软脉颗粒组明显优于对照组。</p></sec><sec id="s8_5"><title>4.5. 治疗后两组患者中医临床疗效比较</title><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Clinical effect of TCM Syndrome in two groups after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >显效</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >总有效率</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >65.0%</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >90.0%</td></tr></tbody></table></table-wrap><p>表5. 治疗后两组患者中医证候临床疗效</p><p>注：X<sup>2</sup>检验，P &lt; 0.05。</p><p>表5显示：对照组的总有效率达65.0%，补心软脉组的总有效率达90.0%，两组患者中医证候疗效采用X<sup>2</sup>检验进行统计分析，X<sup>2</sup> = 6.468，P = 0.039，有统计学差异，说明治疗后较治疗前中医证候明显改善，而且与对照组相比较，治疗组疗效更佳。</p></sec><sec id="s8_6"><title>4.6. 治疗前后两组患者血脂水平比较</title><p>表6显示：治疗前两组血脂水平无明显差异；经治疗后，两组患者TC、TG、LDL、HDL较治疗前均有所下降，P=0.028，有统计学意义；治疗后两组间血脂对比，P = 0.037，有统计学意义，说明治疗组能明显降低TC、TG、LDL-C、HDL-C的水平，优于对照组。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Comparison of blood lipid levels between the two groups before and after treatment ( X &#175; &#177; S</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >TC</th><th align="center" valign="middle" >TG</th><th align="center" valign="middle" >LDL-C</th><th align="center" valign="middle" >HDL-C</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >对照组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5.91 &#177; 0.76</td><td align="center" valign="middle" >2.11 &#177; 0.13</td><td align="center" valign="middle" >3.94 &#177; 0.68</td><td align="center" valign="middle" >0.87 &#177; 0.12</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5.47 &#177; 0.75</td><td align="center" valign="middle" >1.93 &#177; 0.25</td><td align="center" valign="middle" >3.54 &#177; 0.65</td><td align="center" valign="middle" >0.56 &#177; 0.13</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >治疗组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5.89 &#177; 0.77</td><td align="center" valign="middle" >2.12 &#177; 0.14</td><td align="center" valign="middle" >3.92 &#177; 0.67</td><td align="center" valign="middle" >0.73 &#177; 0.11</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5.27 &#177; 0.73<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >1.89 &#177; 0.13<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >3.15 &#177; 0.66<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >0.45 &#177; 0.14<sup>*</sup><sup>△</sup></td></tr></tbody></table></table-wrap><p>表6. 治疗前后两组患者血脂水平比较( X &#175; &#177; S)</p><p>注：治疗前两组间对比，P &gt; 0.05；治疗后与治疗前相比，*P &lt; 0.05；治疗后两组间对比，△P &lt; 0.05。</p></sec><sec id="s8_7"><title>4.7. 治疗前后两组患者血流变学比较</title><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Comparison of hemorheology between two groups before and after treatment ( X &#175; &#177; S</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >全血高切</th><th align="center" valign="middle" >全血低切</th><th align="center" valign="middle" >血浆粘度</th><th align="center" valign="middle" >红细胞刚性指数</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >对照组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4.52 &#177; 0.24</td><td align="center" valign="middle" >7.99 &#177; 0.95</td><td align="center" valign="middle" >1.57 &#177; 0.17</td><td align="center" valign="middle" >7.84 &#177; 0.51</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >3.85 &#177; 0.27</td><td align="center" valign="middle" >7.44 &#177; 0.89</td><td align="center" valign="middle" >1.52 &#177; 0.16</td><td align="center" valign="middle" >7.12 &#177; 0.59</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >治疗组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4.56 &#177; 0.26</td><td align="center" valign="middle" >8.24 &#177; 0.98</td><td align="center" valign="middle" >1.61 &#177; 0.16</td><td align="center" valign="middle" >7.73 &#177; 0.58</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >3.45 &#177; 0.17<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >6.63 &#177; 0.87<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >1.39 &#177; 0.14*<sup>△</sup></td><td align="center" valign="middle" >6.88 &#177; 0.43*<sup>△</sup></td></tr></tbody></table></table-wrap><p>表7. 治疗前后两组患者血流变学比较( X &#175; &#177; S)</p><p>注：治疗前两组间对比，P &gt; 0.05；治疗后与治疗前相比，*P &lt; 0.05；治疗后两组间对比，△P &lt; 0.05。</p><p>表7显示：采用独立样本t检验对两组治疗前血液流变学进行统计分析，P &gt; 0.05，无统计学差异，具有可比性；治疗组治疗后全血高切、低切、血浆粘度、红细胞刚性指数水平均有所下降，与治疗前相比，有统计学意义(P &lt; 0.05)；治疗后两组间对比，P = 0.041，说明补心软脉组能显著改善患者的血液流变学，疗效优于对照组。</p></sec><sec id="s8_8"><title>4.8. 治疗前后两组患者hs-CRP、D-D二聚体、纤维蛋白原水平比较</title><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> The levels of hs-CRP, D-D dimer and fibrinogen in the two groups before and after treatment ( X &#175; &#177; S</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >hs-CRP</th><th align="center" valign="middle" >D-D二聚体</th><th align="center" valign="middle" >纤维蛋白原(FB)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >对照组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5.49 &#177; 0.86</td><td align="center" valign="middle" >2.03 &#177; 1.12</td><td align="center" valign="middle" >3.97 &#177; 1.13</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >3.26 &#177; 0.34<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >1.23 &#177; 0.86<sup> *</sup><sup>△</sup></td><td align="center" valign="middle" >2.57 &#177; 1.27<sup>*</sup><sup>△</sup></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >治疗组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5.35 &#177; 1.08</td><td align="center" valign="middle" >2.09 &#177; 1.08</td><td align="center" valign="middle" >4.01 &#177; 1.22</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2.57 &#177; 0.39<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >0.66 &#177; 0.42 <sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >2.19 &#177; 0.68<sup>*</sup><sup>△</sup></td></tr></tbody></table></table-wrap><p>表8. 治疗前后两组患者hs-CRP、D-D二聚体、纤维蛋白原水平比较( X &#175; &#177; S)</p><p>注：治疗前两组间对比，P &gt; 0.05；治疗后与治疗前相比，*P &lt; 0.05；治疗后两组间对比，△P &lt; 0.05。</p><p>表8显示：采用独立样本t检验对两组治疗前hs-CRP进行统计分析，P &gt; 0.05，无统计学差异，具有可比性；治疗组治疗后hs-CRP水平均有所下降，与治疗前相比，有统计学意义(P &lt; 0.05)；治疗后两组间对比，P = 0.063，治疗后两组间无明显差异。治疗前两组间D-D二聚体、纤维蛋白原水平利用独立样本t检验进行统计分析，统计量F = 0.324，P = 0.573，无统计学差异；治疗后，与治疗前相比，采用配对样本t检验，两组患者血清中D-D二聚体、纤维蛋白原水平均有下降，P = 0.025，有统计学意义；治疗后两组间对比，P = 0.033，表明补心软脉组在降低D-D二聚体、纤维蛋白原水平方面优于对照组。</p></sec></sec><sec id="s9"><title>5. 讨论</title><p>冠状动脉粥样硬化的发生与脂质代谢紊乱、炎症和氧化应激、内皮功能障碍、血小板聚集及血栓形成等多种因素有关。现代医学对于冠状动脉硬化的研究方法和手段日渐增多，但都不能解决根本问题。中医药的优势日益突出，多方位、多靶点综合调节，改善患者阴阳失衡的病理状态，为未来中西结合心血管病治疗提供新的思路。</p><p>气阴两虚夹有瘀热型冠心病心绞痛患者多因长期烦劳过度，气阴耗伤，气虚不能固摄血管内皮，或阴虚不能濡润脉道，均是导致血管内皮损伤的正虚因素 [<xref ref-type="bibr" rid="hanspub.39927-ref7">7</xref>]，进而成为动脉硬化的启动因素；病久因虚致实，气虚不能运血，血滞脉中，阴虚煎熬血液成瘀血、煎灼津液为痰，痰瘀痹阻，久蕴化热，成就动脉粥样硬化这一物质基础。此时是邪实与正虚并见，瘀热与气阴两虚共存的虚实夹杂之证。针对冠心病心绞痛的上述病机特点，我们创制了具有补益心肾气阴，化瘀清热通络作用的补心软脉颗粒。</p><p>补心软脉颗粒配方由麦冬20 g、山萸肉12 g、红景天12 g、水蛭6 g、银杏叶10 g、虎杖15 g等组成。方中君药麦冬，味甘、微苦，微寒。归胃、肺、心经，功在养阴生津，润肺清心，药理实验证明其能显著提高实验动物耐缺氧能力，增加冠脉流量，对心肌缺血有明显保护作用，并能抗心律失常及改善心肌收缩力 [<xref ref-type="bibr" rid="hanspub.39927-ref8">8</xref>]；臣药红景天，味寒、甘，涩，归脾、肺经，具有益气、清肺，活血、化瘀的功效，实验研究表明红景天能增加血红蛋白数量，提高血氧含量，降低心脏的负荷，增强缺血心脏的泵血功能，加快血流，修复受损的心肌细胞，减少心肌梗塞的面积，对心肌缺氧具有显著的保护作用 [<xref ref-type="bibr" rid="hanspub.39927-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.39927-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.39927-ref11">11</xref>]；另一臣药山茱萸为补益肝肾之阴药，补益心肾力强，药理研究表明山茱萸具有较好的强心、抗休克、抗氧化、降血脂功效 [<xref ref-type="bibr" rid="hanspub.39927-ref12">12</xref>]，与红景天合用，共同辅佐君药益气养阴活血的功能；佐药水蛭，咸、苦，平，归肝经，功在破血通经，逐瘀消癥，具有抗凝血及血小板聚集，抑制血栓形成，同时还可以降脂、抗动脉粥样硬化、降低血粘度的作用 [<xref ref-type="bibr" rid="hanspub.39927-ref13">13</xref>]；另一佐药银杏叶，甘、苦、涩，归心、肺经，具有活血化瘀、通脉舒络的功效，其主要有效成份为黄酮类化合物，能降血脂、扩张血管、促进血液循环、降低心肌耗氧量作用 [<xref ref-type="bibr" rid="hanspub.39927-ref14">14</xref>]，与水蛭共辅红景天活血化瘀之力；虎杖味苦、酸，性微寒，归肝、胆经，具有活血散瘀，祛风通络，清热利湿，解毒化痰功效，研究表明虎杖有明显降压、减慢心率、正性肌力作用，从而改善心脏供血，保护受损心肌，改善心功能 [<xref ref-type="bibr" rid="hanspub.39927-ref15">15</xref>]，能佐诸药以加强养阴清热化痰活血之力。综观全方，既谨守“治病求本”，养阴以濡润脉道，补气以运血，通过扶正来防止瘀血内停，促进血行；又不忘“攻邪治标”，活血化瘀以通络。攻补兼施，标本兼顾，补而不滞，攻而不亏，且有侧重；所选药物性味平和，不温不燥、不偏寒凉，相互配合，充分发挥中医辨证论治的多靶点多环节调节的整体优势，与冠心病心绞痛之主要病机心肾气阴两虚，瘀血阻络比较合拍，甚切冠心病病机之要害。</p></sec><sec id="s10"><title>6. 结论</title><p>本研究结果表明：补心软脉颗粒在缓解心绞痛等症状及改善中医症候方面有满意的疗效，明显减低血清中TC、TG、LDL，提高HDL水平，降低全血粘度、D-D二聚体、纤维蛋白原含量，可能与其调节脂质代谢、改善血液流变学的作用机制密切相关。对照组和治疗组在抑制炎症反应方面无明显差异，可能与样本量偏少，观察疗程短有关。可见补心软脉颗粒多方位、多靶点参与冠心病动脉粥样硬化的全过程，达到增加冠脉血供、改善心肌缺血的目的。</p></sec><sec id="s11"><title>基金项目</title><p>江苏省科技厅科技支撑计划——社会发展项目(BE2011816)；国家中医药管理局全国第五批全国老中医药专家学术继承资助项目；唐蜀华全国名老中医药专家传承工作室资助项目。</p></sec><sec id="s12"><title>文章引用</title><p>严 冬,王 宁,杨 甜. 补心软脉颗粒对气阴两虚夹有瘀热型心绞痛的临床疗效观察Clinical Effect of “BuXinRuanMai”Granule on Angina Pectoris of Qi-Yin Deficiency and Blood Stasis-Heat Type[J]. 中医学, 2021, 10(01): 89-96. https://doi.org/10.12677/TCM.2021.101011</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39927-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">旷惠挑, 等. 冠心病心绞痛临床证型分类探讨[J]. 中医杂志, 1997, 38(12): 782.</mixed-citation></ref><ref id="hanspub.39927-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">马晓昌, 尹太英, 陈可冀, 等. 冠心病中医辨证分型与冠状动脉造影所见相关性比较研究[J]. 中国中西医结合杂志, 2001, 21(9): 654-656.</mixed-citation></ref><ref id="hanspub.39927-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">严冬, 钱玉良. 一种治疗冠心病的中药复方及其制备方法与应用[P]. 中国专利, ZL201010211975.0.</mixed-citation></ref><ref id="hanspub.39927-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">赵林刚, 钱玉良, 许立, 严冬. 补心软脉颗粒对大鼠急性心肌缺血损伤的保护作用[J]. 南京中医药大学学报, 2014, 30(5): 468-470.</mixed-citation></ref><ref id="hanspub.39927-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yan, D., Zhao, L.-L., Yue, B.-W., Qian, H., Zhang, Z.-H., Wang, N., Yan, S.-H., Qian, Y.-L. and Qian, Y.L. (2019) Granule of BU-XIN RUAN-MAI Attenuates the Patients’ Angina Pectoris of Coronary Heart Disease via Regulating miR-542-3p/GABARAP Signaling. Evidence-Based Complementary and Alternative Medicine, 2019, Article ID: 1808419. &lt;br&gt;https://doi.org/10.1155/2019/1808419</mixed-citation></ref><ref id="hanspub.39927-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">严冬, 钱玉良, 严士海, 王宁, 周朝伟, 唐蜀华. 补心软脉颗粒含药血清对AngII诱导的HUVEC细胞抗氧化作用[J]. 南京中医药大学学报, 2015, 31(5): 461-464.</mixed-citation></ref><ref id="hanspub.39927-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Lin, S.-Q., Wei, X.-H., Huang, P., et al. (2012) QiShenYiQi Pills Prevents Cardiac Ischemia-Reperfusion Injury via Energy Modulation. International Journal of Cardiology, 168, 967-974.</mixed-citation></ref><ref id="hanspub.39927-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">于晓文, 杜鸿志, 孙立, 等. 麦冬皂苷药理作用研究进展[J]. 药学进, 2014, 38(4): 279-284.</mixed-citation></ref><ref id="hanspub.39927-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">贾真. 红景天苷对大鼠急性心肌缺血的保护作用[J]. 中医研究, 2015, 28(8): 57-59.</mixed-citation></ref><ref id="hanspub.39927-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">谭洪玲, 肖成荣, 马增春, 等. 红景天苷对心肌细胞缺氧/复氧的保护作用[J]. 解放军药学学报, 2010, 26(3): 194-197.</mixed-citation></ref><ref id="hanspub.39927-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">王文杰, 陈红英, 等. 红景天苷对大鼠心肌缺血预处理后血管内皮生长因子表达的影响[J]. 中国医药导报, 2015, 12(9): 29-33.</mixed-citation></ref><ref id="hanspub.39927-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">宋梅. 山茱萸含量测定和药理作用研究进展[J]. 江苏中医药, 2010, 42(9): 80-81.</mixed-citation></ref><ref id="hanspub.39927-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">瞿新艳. 水蛭的抗凝血作用研究[J]. 现代中西医结合杂志, 2010, 19(13): 1582-1583.</mixed-citation></ref><ref id="hanspub.39927-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">刘花, 高卉. 银杏叶提取物药理作用的研究进展[J]. 湖北科技学院学报, 2015, 29(3): 259-262.</mixed-citation></ref><ref id="hanspub.39927-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">王鸣慧, 牛雯颖, 韩翠翠, 等. 虎杖不同提取物对急性血瘀大鼠血液流变学的影响[J]. 中医药信息, 2010, 27(5): 27-29.</mixed-citation></ref></ref-list></back></article>